Drug intelligence / Profile preview

Dnajc10 plasmid vaccine

Development stage: Preclinical
Lead developer: University of Washington
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Dnajc10 plasmid vaccine is a preclinical DNA plasmid vaccine candidate developed by researchers at the University of Washington. The vaccine consists of a plasmid encoding DnaJ heat shock protein family (Hsp40) member C10 (Dnajc10), which was identified as a pre-diagnostic tumor antigen in transgenic mouse models of breast cancer. By delivering the plasmid encoding Dnajc10, the vaccine is designed to stimulate a targeted immune response against breast cancer cells expressing this antigen. In preclinical implant models, vaccination with the Dnajc10 plasmid has demonstrated significant tumor growth inhibition.

Targets

HSP (Heat shock proteins)

Beyond the preview

Go deeper on Dnajc10 plasmid vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dnajc10 plasmid vaccine.

Explore the full profile